Medication info
Daiwoo Rosuvastatin Tablet 5 mg (Rosuvastatin Calcium (Unmicronized))

Daiwoo Rosuvastatin Tablet 5 mg (Rosuvastatin Calcium (Unmicronized))

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium Micronized›5.2mg / 1 tablet
Manufacturer / importer
Daiwoo Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201000975 · Approved 2010.01.28 · Insurance code 641604580

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. The dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response. The dose may be increased to a maximum of 20 milligrams per day. 3. Older adults : No dose adjustment is required. 4. Patients with renal impairment : No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy : The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.
Child dose
Heterozygous familial hypercholesterolemia in pediatric patients (aged 10 to 17 years): The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or more. Safety and efficacy have not been established in children younger than 10 years.

Ingredients

Manufacturer
Daiwoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • familial dyslipidemia
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • early coronary artery disease family history
View approved original text

This medication is primarily used as an adjunct when dietary changes and exercise are insufficient for controlling primary hypercholesterolemia and mixed dyslipidemia. Additionally, it is used as an adjunct to other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia. It helps lower total cholesterol and LDL cholesterol levels, thus slowing the progression of atherosclerosis. In particular, it is also used as an adjunct to diet in patients aged 10 to 17 who meet specific criteria for hypercholesterolemia. It is also applied as an adjunct to diet in patients with primary dysbetalipoproteinemia. Lastly, it helps reduce the risk of stroke, myocardial infarction, and peripheral revascularization in high-risk patients aged middle-aged and above. This medication is used to improve cholesterol levels and reduce the risk of cardiovascular diseases.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. The dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response. The dose may be increased to a maximum of 20 milligrams per day. 3. Older adults : No dose adjustment is required. 4. Patients with renal impairment : No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy : The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Child dose

Heterozygous familial hypercholesterolemia in pediatric patients (aged 10 to 17 years): The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or more. Safety and efficacy have not been established in children younger than 10 years.

Precautions

This medication should not be administered to certain patients. For example, it should not be used in patients who are allergic to it, have severe hepatic impairment, have muscle disorders, are taking certain immunosuppressants, have severe renal impairment, are pregnant or breastfeeding women, and in fertile women who do not use adequate contraception. Additionally, high-dose administration is contraindicated in patients at high risk for muscle disorders, and it should not be administered to patients with lactose intolerance. This medication should be used with caution in patients with weak liver function or those who consume alcohol excessively, and regular liver function tests should be conducted before and during treatment. If symptoms of muscle pain or weakness occur, notify healthcare professionals immediately. If necessary, blood tests should be conducted to check for muscle damage. In cases of acute severe illness or after surgery, administration of this medication may need to be discontinued. While taking this medication, there may be interactions with other drugs, so it is essential to inform healthcare professionals about any other medications being taken. Pregnant or breastfeeding women should not use this medication, and fertile women should use appropriate methods of contraception to prevent pregnancy. In case of overdose, there is no specific antidote, so symptomatic treatment and liver and muscle enzyme tests are required. This medication is known not to have a significant effect on driving or operating machinery; however, dizziness may occur, so caution is advised. Lastly, the plasma concentration of this medication may be higher in Asians, necessitating dose adjustment.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, drug-induced lichenoid rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, increased CK, increased AST, joint pain, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, myalgia, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is best to store it at room temperature between 1 degrees and 30 degrees Celsius. Proper storage helps maintain the medication's efficacy longer.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.